Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: J&J looks to Tremfya as Stelara declines; Pfizer’s Hympavzi may find hemophilia B niche; big pharma’s cell and gene therapy realities; M&A took a holiday in Q3; and last rites for Sanofi’s RIPK1 drug.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

More from Scrip's Five Must-Know Things

More from Scrip